USPTO serial 79408547
Reviewed by CopyMark Law Group
Status 700 means the trademark is registered and active on the Principal Register. You have nationwide rights for the listed goods and services and may use ®. Section 8 maintenance is due between years five and six. Calendar Section 8 between years five and six, and consider trademark monitoring.
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Lindsay M.R. Jones
Lindsay M.R. Jones Merchant & Gould, P.C.P.O. Box 2910Minneapolis, MN 55402United States| Class | Description | Status | First use |
|---|---|---|---|
| 035 | Commercial consulting concerning the business development and marketing of cosmetic products, pharmaceuticals, nutraceuticals, medicines, food supplements, and medical apparatus and devices; conducting market studies; advice regarding public relations communication strategies relating to cosmetic, pharmaceutical, and nutraceutical products, medication, food supplements, and medical devices and apparatus, namely, public relations and media relations; setting up communication tools, namely, providing public relations and media relations in the context of the commercial introduction of cosmetic products, pharmaceuticals, nutraceuticals, medicine, food supplements, and medical apparatus and devices; commercial advice in the nature of business advice relating to the import and export of cosmetic products, pharmaceuticals, nutraceuticals, medicines, food supplements, and medical apparatus and devices | ACTIVE | — |
| 042 | Providing scientific research and technology research services in the field of developing pharmaceuticals, nutraceuticals, cosmetic products, medicine, food supplements, and medical apparatus and devices; technical project studies in the nature of conducting scientific and technological feasibility studies in the field of development of pharmaceutical, nutraceutical, and cosmetic products, medicine, food supplements, and medical apparatus and devices; technical and scientific assistance, namely, technical writing for others of user instructions for pharmaceutical, nutraceutical, and cosmetic products, medicine, food supplements, and medical apparatus and devices; providing scientific research information in the nature of data and results from scientific, pharmaceutical, clinical, biological, and medical research and development from an online searchable database; conducting scientific, pharmaceutical, clinical trial, biological, and medical research services using databases; hosting the software of others for the provision of information, results, and data relating to scientific, pharmaceutical, clinical, biological, and medical research and development; design of software and database systems for the provision of information, results, and data relating to scientific, pharmaceutical, clinical, biological, and medical research and development; installation of software for the provision of information, results, and data relating to the scientific, pharmaceutical, clinical, biological, and medical research and development; updating and maintenance of software and database systems for the provision of information, results, and data relating to scientific, pharmaceutical, clinical, biological, and medical research and development; computer services, namely, providing electronic storage of data with respect to scientific, pharmaceutical, clinical, biological, and medical research and development; providing temporary use of online non-downloadable computer software for analysing data in the fields of scientific, pharmaceutical, clinical, biological, and medical research and development; providing internet search engines in the field of scientific, pharmaceutical, clinical, biological, and medical data and information; computer technology consultancy services with respect to computer database programs and systems relating to the provision of information, results, and data with respect to scientific, pharmaceutical, clinical, biological, and medical research and development | ACTIVE | — |
| 045 | Regulatory compliance consulting and legal advice, all in the field of development, implementation, and marketing of pharmaceutical, nutraceutical, and cosmetic products, medicine, food supplements, and medical apparatus and devices; regulatory compliance consulting and legal advice, all in the field of drawing up user instructions for pharmaceutical, nutraceutical, and cosmetic products, medicine, food supplements, and medical apparatus and devices; legal information and legal advice for obtaining legal authorizations for marketing of pharmaceutical, nutraceutical, and cosmetic products, medicine, food supplements, and medical apparatus and devices | ACTIVE | — |
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
| Date | Code | Event | What it means |
|---|---|---|---|
| Oct 7, 2026 | FICR | FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB | — |
| Jul 7, 2026 | NRCC | NOTICE OF REGISTRATION CONFIRMATION EMAILED | — |
| Jul 7, 2026 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| May 19, 2026 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| May 19, 2026 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| May 13, 2026 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Apr 24, 2026 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Apr 24, 2026 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Apr 24, 2026 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Apr 24, 2026 | ERFR | TEAS REQUEST FOR RECONSIDERATION RECEIVED | — |
| Apr 16, 2026 | OPNX | NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB | — |
| Mar 30, 2026 | OPNS | NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB | — |
| Mar 29, 2026 | OPNR | NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB | — |
| Nov 5, 2025 | GNFN | NOTIFICATION OF FINAL REFUSAL EMAILED | — |
| Nov 5, 2025 | GNFR | FINAL REFUSAL E-MAILED | A final Office Action (final refusal) means the examining attorney is maintaining at least one refusal and your options are narrower. You can file a response addressing the refusal, appeal to the Trademark Trial and Appeal Board, or let the application abandon. |
| Nov 5, 2025 | CNFR | FINAL REFUSAL WRITTEN | A final Office Action (final refusal) means the examining attorney is maintaining at least one refusal and your options are narrower. You can file a response addressing the refusal, appeal to the Trademark Trial and Appeal Board, or let the application abandon. |
| Oct 3, 2025 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Oct 3, 2025 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Oct 3, 2025 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Apr 19, 2025 | RFNT | REFUSAL PROCESSED BY IB | — |
| Apr 3, 2025 | RFCS | NON-FINAL ACTION MAILED - REFUSAL SENT TO IB | — |
| Apr 3, 2025 | RFRR | REFUSAL PROCESSED BY MPU | — |
| Feb 28, 2025 | RFCR | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW | — |
| Feb 27, 2025 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Feb 25, 2025 | DOCK | ASSIGNED TO EXAMINER | — |
| Nov 4, 2024 | MAFR | APPLICATION FILING RECEIPT MAILED | — |
| Nov 4, 2024 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Oct 31, 2024 | REPR | SN ASSIGNED FOR SECT 66A APPL FROM IB | — |